We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

93 hedge funds and large institutions have $129M invested in Palvella Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 34 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $99M → $129M (+$29.8M)

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

1% more funds holding

Funds holding: 92 → 93 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.06% less ownership

Funds ownership: 0.75% → 0.7% (-0.06%)

29% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 34

Holders
93
Holders Change
+1
Holders Change %
+1.09%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
24
Reduced
34
Closed
12
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
+$5K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$2.42M
2
N
Nuveen
North Carolina
+$2.39M
3
ACM
Aquilo Capital Management
California
+$899K
4
OAM
Oxford Asset Management
United Kingdom
+$657K
5
FI
Fosun International
China
+$529K

Top Sellers

1
TCM
Tekla Capital Management
Massachusetts
-$2.38M
2
WCM
Wedge Capital Management
North Carolina
-$1.76M
3
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$1.41M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.37M
5
Bank of America
Bank of America
North Carolina
-$1.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
101
Two Sigma Investments
New York
– -$97K -364 Closed
Man Group
102
Man Group
United Kingdom
– -$51K -190 Closed
CS
103
Credit Suisse
Switzerland
– -$42K -159 Closed
CHP
104
Cable Hill Partners
Oregon
– -$23K -88 Closed
RBC
105
Roble Belko & Company
Pennsylvania
– -$7K -26 Closed
1 2 3 4
5

PVLA Hedge Fund Activity: Q2 2019 in Review

93 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2019, worth a combined $129M — up 30% from $99M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PVLA positions and 12 closed out — a net gain of 3 holders — while 24 added to existing stakes and 34 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.42M. The largest seller was Tekla Capital Management, cutting an estimated $2.38M.

  • 93 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2019, up from 92 in Q1 2019.
  • Funds reported $129M of Palvella Therapeutics stock for Q2 2019, up 30% quarter-over-quarter.
  • 15 funds opened new Palvella Therapeutics positions in Q2 2019 and 12 closed out, a net change of +3 holders.
  • The largest Palvella Therapeutics buyer in Q2 2019 was Millennium Management, an estimated $2.42M added.
  • The largest Palvella Therapeutics seller in Q2 2019 was Tekla Capital Management, an estimated $2.38M sold.

Based on aggregated 13F filings for Q2 2019.